Anti-protease Treatments Targeting Plasmin(ogen) and Neutrophil Elastase May Be Beneficial in Fighting COVID-19
| Autor: | Alain R. Thierry |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Coronavirus disease 2019 (COVID-19)
Physiology Plasmin Pneumonia Viral neutrophil extracellular traps Comorbidity Microbiology Betacoronavirus Risk Factors Physiology (medical) medicine elastase Humans Fibrinolysin Letter to the Editor Pandemics Molecular Biology COVID plasmin Anti proteases Respiratory Distress Syndrome treatment biology SARS-CoV-2 Chemistry Elastase COVID-19 Plasminogen General Medicine Neutrophil extracellular traps biology.organism_classification Neutrophil elastase Host-Pathogen Interactions biology.protein Disease Susceptibility Coronavirus Infections medicine.drug |
| Zdroj: | Physiological Reviews |
| ISSN: | 1522-1210 0031-9333 |
| DOI: | 10.1152/physrev.00019.2020 |
| Popis: | Patients with hypertension, diabetes, coronary heart disease, cerebrovascular illness, chronic obstructive pulmonary disease, and kidney dysfunction have worse clinical outcomes when infected with SARS-CoV-2, for unknown reasons. The purpose of this review is to summarize the evidence for the existence of elevated plasmin(ogen) in COVID-19 patients with these comorbid conditions. Plasmin, and other proteases, may cleave a newly inserted furin site in the S protein of SARS-CoV-2, extracellularly, which increases its infectivity and virulence. Hyperfibrinolysis associated with plasmin leads to elevated D-dimer in severe patients. The plasmin(ogen) system may prove a promising therapeutic target for combating COVID-19. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|